Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans

A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus Infection

1991 • 248 citations

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4

1988 • 231 citations

Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay

1988 • 205 citations

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

1993 • 196 citations

The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans

1991 • 170 citations

Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults

1993 • 160 citations

Induction of CD4⁺Human Cytolytic T Cells Specific for HIV-Infected Cells by a Gp160 Subunit Vaccine

1990 • 148 citations

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

1993 • 118 citations

Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1

1994 • 110 citations

Candidate AIDS Vaccines

1995 • 104 citations

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network

1994 • 96 citations

Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.

1992 • 94 citations

Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection

1993 • 84 citations

An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.

1993 • 45 citations

Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

1993 • 44 citations

Human Immunodeficiency Virus (HIV-l) gp160-Specific Lymphocyte Proliferative Responses of Mononuclear Leukocytes from HIV-l Recombinant gp160 Vaccine Recipients

1991 • 43 citations

Persisting Human Immunodeficiency Virus Type 1 gp160-Specific Human T Lymphocyte Responses Including CD8+ Cytotoxic Activity after Receipt of Envelope Vaccines

1993 • 40 citations

Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160

1992 • 38 citations

Human trials of experimental AIDS vaccines

1993 • 37 citations

Primate models for HIV vaccines

1993 • 31 citations

Lymphoproliferative Responses to Mitogens and HIV-1 Envelope Glycoprotein Among Volunteers Vaccinated with Recombinant gp160

1990 • 27 citations

Human Immunodeficiency Virus Vaccines

1993 • 26 citations

The Quest for an AIDS Vaccine: The State of the Art and Current Challenges

1991 • 22 citations

Cited By (0)

Loading...